Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + Imprime PGG
- Development stage
- Unknown
- Lead developer
- HiberCell
- Modality
- Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cetuximab + Imprime PGG is an investigational combination therapy for cancer. Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting ligand binding and downstream signaling and mediating antibody-dependent cellular cytotoxicity. Imprime PGG (also known as BTH-1677 or odetiglucan) is a soluble beta-glucan immunomodulator that acts as a pathogen-associated molecular pattern to stimulate innate immune cells via Dectin 1 and Fc gamma receptor IIA pathways. The combination aims to enhance anti-tumor immune responses by leveraging both direct EGFR inhibition and innate/adaptive immune activation. This regimen has been studied in metastatic colorectal cancer (mCRC) with KRAS wild-type tumors and non-small cell lung cancer (NSCLC), showing improved objective response rates compared to historical controls or standard regimens[2][3][4][5].
- Brand names
- Erbitux
- Other names
- BTH-1677BTH1677BTH 1677beta-glucan PGGodetiglucan
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)CLEC7A (Dectin-1)FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)αMβ2 (Integrin αMβ2)
Beyond the preview
Go deeper on cetuximab + Imprime PGG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + Imprime PGG.